PMID- 35694257
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - A Leukocyte Migration Assay Assists Understanding of Interleukin-1beta-Induced 
      Leukocyte Migration Into Preterm Mouse Uterus.
PG  - 898008
LID - 10.3389/fphar.2022.898008 [doi]
LID - 898008
AB  - Neutrophils and other leukocytes invade the mouse uterus at term birth, which is 
      normal for activating the uterus for labor. To better understand the regulation 
      of this migration at term and interleukin (IL)-1beta-induced preterm birth, we 
      developed a mouse leukocyte migration assay (mLMA) and used it with rytvela, an 
      IL-1 receptor allosteric antagonist. The mLMA uses term peripheral blood 
      leukocytes that migrate in a Boyden chamber in response to a chemoattractant. We 
      tested several mouse uterine tissues after homogenization and sedimentation of 
      debris for chemoattractant activity. The most active chemoattractant homogenate 
      came from the mouse lower uterus on gestational day (GD) 18.5. Using flow 
      cytometry, we demonstrated that 99% of the cells that migrate are neutrophils. 
      IL-1beta administered on GD 16 stimulated neutrophil migration and invasion into the 
      uterus and the fetal brain along with preterm birth on GD 17. Preterm birth and 
      the increased leukocyte invasion of the maternal uterus and fetal brain were all 
      blocked by the co-administration of rytvela. To test where the site of IL-1beta 
      action might be, we examined the potency of lower uterine chemoattractant and the 
      activation of leukocytes following IL-1beta +/- rytvela administration. IL-1beta did 
      not increase lower uterus homogenate chemoattractant activity, but it 
      significantly (p < 0.05) increased leukocyte activation as defined by cytokine 
      and chemokine expression. Rytvela blocked this activation of leukocytes by IL-1beta. 
      We conclude that IL-1beta stimulates preterm birth in mice by increasing leukocyte 
      activation leading to increased uterine and fetal brain leukocyte invasion.
CI  - Copyright (c) 2022 Lee, Patel, Onushko, Fang, Chemtob and Olson.
FAU - Lee, Han
AU  - Lee H
AD  - Olson Laboratory, Department of Physiology, University of Alberta, Edmonton, AB, 
      Canada.
FAU - Patel, Vaishvi
AU  - Patel V
AD  - Olson Laboratory, Faculty of Science, University of Alberta, Edmonton, AB, 
      Canada.
FAU - Onushko, Meghan
AU  - Onushko M
AD  - Olson Laboratory, Faculty of Science, University of Alberta, Edmonton, AB, 
      Canada.
FAU - Fang, Xin
AU  - Fang X
AD  - Olson Laboratory, Department of Obstetrics/Gynecology, University of Alberta, 
      Edmonton, AB, Canada.
FAU - Chemtob, Sylvain
AU  - Chemtob S
AD  - Chemtob Laboratory, Departments of Pediatrics and Ophthalmology/Pharmacology, 
      University of Montreal, Montreal, QC, Canada.
FAU - Olson, David
AU  - Olson D
AD  - Olson Laboratory, Department of Physiology, University of Alberta, Edmonton, AB, 
      Canada.
AD  - Olson Laboratory, Department of Obstetrics/Gynecology, University of Alberta, 
      Edmonton, AB, Canada.
AD  - Olson Laboratory, Department of Pediatrics, University of Alberta, Edmonton, AB, 
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20220525
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9174527
OTO - NOTNLM
OT  - chemotaxis
OT  - fetal
OT  - inflammation
OT  - leukocyte migration assay
OT  - mouse
OT  - neutrophils
OT  - preterm birth
OT  - rytvela
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/14 06:00
MHDA- 2022/06/14 06:01
PMCR- 2022/05/25
CRDT- 2022/06/13 03:29
PHST- 2022/03/16 00:00 [received]
PHST- 2022/04/18 00:00 [accepted]
PHST- 2022/06/13 03:29 [entrez]
PHST- 2022/06/14 06:00 [pubmed]
PHST- 2022/06/14 06:01 [medline]
PHST- 2022/05/25 00:00 [pmc-release]
AID - 898008 [pii]
AID - 10.3389/fphar.2022.898008 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 May 25;13:898008. doi: 10.3389/fphar.2022.898008. 
      eCollection 2022.